Summary
Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is important in the management of these tumors, but current imaging methods have limitations in providing the necessary information for optimal treatment of these patients. The goal of this study is to evaluate the potential utility of positron emission tomography (PET) with 3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) in the medical management of brain tumors in children. Funding source - FDA Office of Orphan Product Development (OOPD)
Conditions
Brain Neoplasms
Recruitment Status
Completed
Detailed Description
Although pediatric central nervous system tumors are rare, they are a significant contributor to morbidity and mortality in children. Tumor staging, detecting recurrent tumor, and assessing the response to therapy are critical in the treatment of brain tumors, but current imaging methods have major limitations in providing such information. The objective of this study is to validate 3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) as a measure of tumor proliferation and to demonstrate the utility of 18F-FLT as a PET imaging agent in children with central nervous system tumors. The proposed studies will evaluate 18F-FLT PET in three groups: Children with a new diagnosis of central nervous system tumor. Children in whom conventional imaging has raised concern for possible recurrence of a central nervous system tumor. Children receiving post-operative chemotherapy for a central nervous system tumor. In these three groups, correlation of 18F-FLT uptake with tumor histopathology and patient outcome will be used to assess the utility of 18F-FLT for grading tumors at diagnosis, for accurate identification of tumor recurrence, and for early assessment of the response to chemotherapy.
Eligibility Criteria
Inclusion Criteria:
age 21 years or less
capable of achieving imaging without need for sedation or anesthesia (typically age 8 years or greater, but there is no lower limit for age for eligibility)
Karnofsky Performance Status of 50 or greater in subjects age 12 years or greater, for age less than 12 years a Lansky play scale of 50% or greater
Patients receiving steroids and/or anti-seizure medications are eligible
Exclusion Criteria:
clinically active infection
pregnancy or breast-feeding
serious intercurrent medical illness
require emergency surgical intervention that would be inappropriately delayed by FLT-PET imaging
Intervention
Intervention Type
Intervention Name
Drug
[18F] FLT
Phase
Phase 2
Gender
All
Min Age
N/A
Max Age
21 Years
Download Date
August 1, 2023
Principal Investigator
Frederick Daniel Grant
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team: